Drugs Made In America Acquisition Corp. (DMAAR) Current Assets (2024 - 2026)

Drugs Made In America Acquisition (DMAAR) has reported Current Assets for 3 consecutive years, with $69184.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Current Assets rose 39.13% year-over-year to $69184.0; the trailing twelve-month figure through Jun 2026 stood at $69184.0 (up 39.13% YoY), and the FY2025 full-year result was $12191.0, up 144.26% from the prior year.
• Current Assets improved to $69184.0 in Q2 2026 per DMAAR's latest filing, from $12191.0 in the prior quarter.
• Across five years, Current Assets topped out at $71019.0 in Q1 2025 and bottomed at $4991.0 in Q4 2024.
• Historically, Current Assets has averaged $39217.8 across 3 years, with a median of $38961.0 in 2025.
• The sharpest annual moves came in 2025 and 2026: Current Assets jumped 144.26% in 2025, then surged 39.13% in 2026.
• Over 3 years, Current Assets stood at $4991.0 in 2024, then surged by 144.26% to $12191.0 in 2025, then surged by 467.5% to $69184.0 in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $69184.0, $12191.0, and $28196.0 for Q2 2026, Q4 2025, and Q3 2025 respectively.